In Alligator’s research projects, the company lays the foundation to continuously develop the pipeline of innovative drug candidates for tumor-directed immunotherapy. The company bases its research on its expertise within the TNF receptor superfamily (TNFRSF) and develops new mono- and bispecific antibodies in this field, internally as well as in collaboration with international biotech and pharma companies.
In one such research project, the aim is to develop an agonistic monospecific antibody that activates a TNFRSF member. It has been developed using the antibody library ALLIGATOR-GOLD®. Antibodies against this receptor are already in early clinical development. The antibody has been developed in order to be "best in class" with a clear differentiation against competitors. The development of the product candidate has progressed rapidly, and cell line development for manufacturing of clinical material will start in the first half of 2017.
In another research project, a bispecific agonistic antibody that binds to a TNFRSF member and another target protein is developed. The product components were generated using ALLIGATOR-GOLD® and FIND®.